Drug Type Small molecule drug |
Synonyms OX-MPI, BI-1029539, GS 248 + [1] |
Target |
Mechanism PGES inhibitors(Prostaglandin E synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC30H34Cl2F5N5O3 |
InChIKeyPFORUFFGGNOLPJ-QAQDUYKDSA-N |
CAS Registry1360622-01-0 |
Start Date29 Dec 2020 |
Sponsor / Collaborator Gesynta Pharma ABStartup [+1] |
Start Date02 Nov 2020 |
Sponsor / Collaborator Gesynta Pharma ABStartup |
Start Date31 Mar 2020 |
Sponsor / Collaborator Gesynta Pharma ABStartup [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Microvascular Disease | Phase 2 | US | Gesynta Pharma ABStartup | 30 Jan 2022 |
Microvascular Disease | Phase 2 | US | 30 Jan 2022 | |
Raynaud Disease | Phase 2 | BE | Gesynta Pharma ABStartup | 29 Dec 2020 |
Raynaud Disease | Phase 2 | NL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Raynaud Disease | Phase 2 | PL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Raynaud Disease | Phase 2 | GB | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | BE | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | NL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | PL | Gesynta Pharma ABStartup | 29 Dec 2020 |
Retinitis Pigmentosa | Phase 2 | GB | Gesynta Pharma ABStartup | 29 Dec 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 94 | (GS-248) | nhirlxrxlt(rrghbhwukk) = wywegrecjz ncejsochuz (lefylcwixf, jqltqawini - ulpmwvjyjv) View more | - | 09 Aug 2024 | ||
Placebo (Placebo) | nhirlxrxlt(rrghbhwukk) = vndthrmkbv ncejsochuz (lefylcwixf, jluvfwkaga - vnbthymgaf) View more | ||||||
Phase 1 | - | 14 | (Part I GS-248 Formulation A) | lecmwedpzg(tchdgxpapw) = kjydfvtunu hrtojuwjrh (flvdczjkbg, mcluziawlj - nbkplcvkxo) View more | - | 31 Aug 2021 | |
(Part I GS-248 Formulation B) | lecmwedpzg(tchdgxpapw) = hflajseggv hrtojuwjrh (flvdczjkbg, rccfrnxven - rprijerszu) View more |